There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Stoke Therapeutics (STOK) with bullish sentiments.
Biogen (BIIB)
Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Biogen yesterday and set a price target of $350.00. The company’s shares closed last Thursday at $278.70.
According to TipRanks.com, Kulkarni is a 5-star analyst with an average return of 23.7% and a 53.0% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Zynerba Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Biogen with a $312.16 average price target, which is a 10.6% upside from current levels. In a report issued on July 8, SunTrust Robinson also reiterated a Buy rating on the stock with a $330.00 price target.
See today’s analyst top recommended stocks >>
Stoke Therapeutics (STOK)
In a report released yesterday, Michelle Gilson from Canaccord Genuity reiterated a Buy rating on Stoke Therapeutics, with a price target of $44.00. The company’s shares closed last Thursday at $23.15.
According to TipRanks.com, Gilson is a 5-star analyst with an average return of 32.0% and a 56.2% success rate. Gilson covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Eloxx Pharmaceuticals, and Homology Medicines.
Currently, the analyst consensus on Stoke Therapeutics is a Moderate Buy with an average price target of $37.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
